Press release



Saint Pierre, Monday, September 18, 2023.

LOGIPREN receives CE Mark as a medical device in line with the new European regulation.

LOGIPREN, an e-prescribing software dedicated to neonatal and paediatric hospital units, is among the first electronic systems to receive this certification, confirming its compliance with the new standards for security and performance.

The European regulation around the marketing of medical devices is constantly evolving. Before going to market for sale, these healthcare products need to be reviewed against security and performance standards. This review is performed by a notified body through a specific CE Marking process (medical CE marking). The higher the risk class that the medical device falls under, the stricter the conditions are to obtain the certification.

This regulation was completely overhauled when the new European regulation 2017/745 was implemented, considerably increasing the prerequisites necessary to obtain a medical CE Mark.

LOGIPREN: A company committed to quality and reliability

Since February 2023, LOGIPREN is certified compliant with the requirements of ISO 13485:2016, a standard relative to Quality Management Systems.

On 28 August 2023, e-prescribing system LOGIPREN received a CE Mark in accordance with the European Union's new Regulation (EU) 2017/745 relative to medical devices, under class IIb (devices with high/important potential risk). This certification was delivered by Notified Body G-MED.

"At LOGIPREN we've always had high quality standards, just like those held by the

healthcare professionals working in hospitals. We aim for excellence in the services we

provide, living up to the trust placed in us by the 86 healthcare institutions that use our

software. The CE Mark is a new chapter in the life of the company, the fruit of three years of

work and a significant mark of recognition for our team, who is always guided in its work by

quality," highlights Dr Béatrice GOUYON, President of LOGIPREN, the company that bears

the name of its product.

About LOGIPREN

LOGIPREN's mission is to help healthcare professionals (doctors, nurses, pharmacists)

take care of neonates, infants and children who are very sick and hospitalised.

LOGIPREN rests on a proprietary database that simplifies prescribing and codifies

care. The software cross-references patient data with the chosen medication to help

healthcare professionals make the right decisions. LOGIPREN automatically performs

all calculations linked to medication prescribing, thus reducing the amount of

medication errors.

The system also extracts and anonymises prescription data which then feeds into a

database for research purposes.

LOGIPREN was founded by a paediatrician who remains President of the company.

Press contact:

Alain DITISHEIM

alain.ditisheim@logipren.com

+262 (0)2 62 78 19 11

Developed by LOGIPREM-F, the LOGIPREN v.2.5 software is a class IIb medical device, CE certified by notified body G-MED (CE0459), dedicated to healthcare professionals, and not reimbursed by health insurance organisations. Please

read the instructions in the device's user manual carefully before use. (https://support.logipren.com)

Our website: www.logipren.com